X4 Pharmaceuticals, Inc
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
XFOR$3.25-2.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Redeemable Common Stock and Stockholders’ Equity
CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(In thousands, except share amounts)
| Common Stock · AdditionalPaid-InCapital · AccumulatedOtherComprehensive Loss · AccumulatedDeficit · TotalStockholders’ Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance at December 31, 2021 | 28,127,657 | $28 | $347,374 | $(119) | $(282,871) | $64,412 | |||||
| Issuance of common stock, warrants and prefunded warrants for the purchase of common stock, net of issuance costs of $4.7 million | 92,461,988 | 92 | 59,270 | 59,362 | |||||||
| Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations | 372,831 | — | (13) | (13) | |||||||
| Exercise of warrants and prefunded warrants | 499,871 | 1 | 1 | ||||||||
| Stock-based compensation expense | 5,199 | 5,199 | |||||||||
| Issuance of shares of common stock under employee stock purchase plan | 204,903 | 1 | 202 | 203 | |||||||
| Reclassification of warrant liability to equity (Note 13) | 38,754 | 38,754 | |||||||||
| Net loss | (93,867) | (93,867) | |||||||||
| Balance at December 31, 2022 | 121,667,250 | $122 | $450,786 | $(119) | $(376,738) | $74,051 | |||||
| Issuance of common stock, warrants and prefunded warrants for the purchase of common stock, net of issuance costs of $4.6 million | 34,521,046 | 35 | 60,408 | 60,443 | |||||||
| Vesting of restricted stock units, less shares withheld and retired to satisfy tax obligations | 3,510,491 | 2 | (2) | — | |||||||
| Exercise of stock options and warrants | 7,477,845 | 8 | 8,805 | 8,813 | |||||||
| Stock-based compensation expense | 8,687 | 8,687 | |||||||||
| Issuance of shares of common stock under employee stock purchase plan | 257,963 | 272 | 272 | ||||||||
| Net loss | (101,167) | (101,167) | |||||||||
| Balance at December 31, 2023 | 167,434,595 | $167 | $528,956 | $(119) | $(477,905) | $51,099 | |||||
| Issuance of common stock under employee stock purchase plan | 635,542 | 1 | 296 | 297 | |||||||
| Vesting of restricted stock units | 2,876,806 | 3 | (1) | 2 | |||||||
| Stock-based compensation expense | 8,204 | 8,204 | |||||||||
| Unrealized losses on marketable securities | (3) | (3) | |||||||||
| Net loss | (37,450) | (37,450) | |||||||||
| Balance at December 31, 2024 | 170,946,943 | $171 | $537,455 | $(122) | $(515,355) | $22,149 | |||||
| The accompanying notes are an integral part of these consolidated financial statements | |||||||||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.